Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 97–98

HOS-116609 · Präparat HOS-094447

97  Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir: Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose dose: reduction of the DOAC should be dabigatran AUC ↑ 72% considered when a DOAC dabigatran Cmax ↑ 64% transported by P-gp but not metabolised by CYP3A4, darunavir/ritonavir 800/100 mg once including dabigatran etexilate and daily: edoxaban, is co-administered with dabigatran AUC ↑ 18% PREZISTA/rtv. dabigatran Cmax ↑ 22% Darunavir/cobicistat: darunavir/cobicistat 800/150 mg single Clinical monitoring and dose dose: reduction is required when a dabigatran AUC ↑ 164% DOAC transported by P-gp but not dabigatran Cmax ↑ 164% metabolised by CYP3A4, including dabigatran etexilate and darunavir/cobicistat 800/150 mg once edoxaban, is co-administered with daily: PREZISTA/cobi. dabigatran AUC ↑ 88% dabigatran Cmax ↑ 99% Ticagrelor Based on theoretical considerations, Concomitant administration of co-administration of boosted PREZISTA boosted PREZISTA with ticagrelor with ticagrelor may increase is contraindicated (see section 4.3). concentrations of ticagrelor (CYP3A and/or P-glycoprotein inhibition). Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel clopidogrel with boosted PREZISTA is with boosted PREZISTA is not expected to decrease clopidogrel active recommended. Use of other metabolite plasma concentration, which antiplatelets not affected by CYP may reduce the antiplatelet activity of inhibition or induction (e.g. clopidogrel prasugrel) is recommended. Warfarin Not studied. Warfarin concentrations may It is recommended that the be affected when co-administered with international normalised ratio boosted PREZISTA. (INR) be monitored when warfarin is combined with boosted PREZISTA. ANTICONVULSANTS Phenobarbital Not studied. Phenobarbital and phenytoin PREZISTA co-administered with Phenytoin are expected to decrease plasma low dose ritonavir should not be concentrations of darunavir and its used in combination with these pharmacoenhancer. medicines. (induction of CYP450 enzymes) The use of these medicines with PREZISTA/cobicistat is contraindicated (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) phenobarbital (HOS-085617) cobicistat (HOS-088111) dabigatran (HOS-112096) clopidogrel (HOS-087927) edoxaban (HOS-086234) prasugrel (HOS-112066) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531) warfarin (HOS-085950)